EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Barriers to Long-Term Adherence in Botulinum Toxin Therapy for Post-Stroke Spasticity: Insights and Implications from a Single-Center Study in North Italy

Ester Cecchella iD, Nicola Luigi Bragazzi iD, Filippo Cotellessa, William Campanella iD, Luca Puce iD, Lucio Marinelli iD, Antonio Currà iD, Cristina Schenone iD, Laura Mori, Carlo Trompetto iD

Toxins · 2025

DOI: 10.3390/toxins17030102 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Toxins, 2025. Verfasst von Ester Cecchella und 9 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy. Hauptthemen laut MEDLINE: Muscle Spasticity, Stroke, Botulinum Toxins, Medication Adherence. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Stroke is a leading cause of long-term disability worldwide, often resulting in spasticity. Botulinum toxin injections have emerged as a cornerstone in the management of post-stroke spasticity. However, despite their clinical efficacy, maintaining long-term adherence to botulinum toxin therapy remains a significant challenge. This retrospective observational study analyzed 106 patients undergoing botulinum toxin therapy for post-stroke spasticity to identify the key factors influencing treatment continuation. The mean age of the cohort at the time of stroke was 57.7 years, with ischemic strokes accounting for 61.3% of cases and hemorrhagic strokes for 38.7%. A total of 61.3% of patients continued therapy, while 38.7% discontinued therapy due to a variety of reasons. The most common reasons included logistical barriers (43.9%) and comorbidities (36.6%), followed by perceived lack of benefit (24.4%) and clinical resolution (12.2%). Among those citing a lack of benefit, muscular fibrosis was a notable contributor. In the multivariable Cox regression analysis, logistical challenges, such as access to healthcare facilities and administrative difficulties, were associated with discontinuation (HR = 13.95, 95% CI: 5.57–34.94, p < 0.001). Comorbidities also significantly increased the likelihood of discontinuation (HR = 3.51, 95% CI: 1.56–7.87, p = 0.002), as did the lack of benefit (HR = 14.34, 95% CI: 5.65–36.38, p < 0.001) and condition resolution (HR = 19.20, 95% CI: 5.58–66.02, p < 0.001). In contrast, demographic and clinical factors, including age at the time of stroke, gender, stroke type, affected side, and baseline spasticity severity, did not significantly influence treatment continuation. These findings underscore the importance of addressing logistical barriers and mitigating the burden of comorbidities to enhance treatment adherence. A shift toward patient-centered approaches that integrate robust rehabilitation services and streamline healthcare accessibility is critical for optimizing outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscle SpasticityStrokeBotulinum ToxinsMedication AdherenceNeuromuscular AgentsHumansMiddle AgedMaleFemaleRetrospective StudiesItalyAgedAdult

Stichwörter der Autor:innen

Cox regressionKaplan–Meier analysisbotulinum toxinspasticitystrokesurvival analysistreatment discontinuation

Substanzen

Botulinum ToxinsNeuromuscular Agents

Autor:innen und Institutionen

  • IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.
  • Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, 16132 Genoa, Italy.
  • Academic Neurology Unit, A. Fiorini Hospital, 04019 Terracina, Italy.
  • Department of Medico-Surgical Sciences and Biotechnologies, "Sapienza" University of Rome, 00189 Rome, Italy.

ORCID-Profile: Ester Cecchella, Nicola Luigi Bragazzi, William Campanella, Luca Puce, Lucio Marinelli, Antonio Currà, Cristina Schenone, Carlo Trompetto

Förderung

  • Italian Ministry of Health

Zitieren

APA

Cecchella, E., Bragazzi, N. L., Cotellessa, F., Campanella, W., Puce, L., Marinelli, L., Currà, A., Schenone, C., Mori, L., & Trompetto, C. (2025). Barriers to Long-Term Adherence in Botulinum Toxin Therapy for Post-Stroke Spasticity: Insights and Implications from a Single-Center Study in North Italy. Toxins. https://doi.org/10.3390/toxins17030102

Vancouver

Cecchella E, Bragazzi NL, Cotellessa F, Campanella W, Puce L, Marinelli L, et al. Barriers to Long-Term Adherence in Botulinum Toxin Therapy for Post-Stroke Spasticity: Insights and Implications from a Single-Center Study in North Italy. Toxins. 2025. doi:10.3390/toxins17030102

BibTeX
@article{Cecchella2025,
  author = {Cecchella, Ester and Bragazzi, Nicola Luigi and Cotellessa, Filippo and Campanella, William and Puce, Luca and Marinelli, Lucio and Currà, Antonio and Schenone, Cristina and Mori, Laura and Trompetto, Carlo},
  title = {Barriers to Long-Term Adherence in Botulinum Toxin Therapy for Post-Stroke Spasticity: Insights and Implications from a Single-Center Study in North Italy},
  journal = {Toxins},
  year = {2025},
  doi = {10.3390/toxins17030102}
}
Kostenlos starten →